The pharma will vie for amlitelimab’s approval, despite the COAST 2 trial missing a co-primary endpoint.

Fresh data from multiple studies suggest the drug, which Sanofi has billed as a future blockbuster, could be cleared in the U ...

While early, the results indicate drugs known as ITK inhibitors have the potential to match or surpass the efficacy observed ...

After eight weeks, 75% of participants treated with the Corvus pill, called soquelitinib, achieved at least a 75% improvement ...

Apogee Therapeutics (APGE) leverages IL-13 pathway optimization to enable less frequent dosing, targeting a leadership shift ...

Health system pharmacists and clinicians are monitoring a wave of drug approvals expected throughout 2026, including first-in-class therapies and expanded uses of existing drugs with implications for ...

At the 44 th Annual J.P. Morgan Healthcare Conference, Sanofi’s growth and projection for 2026 up until the end of the decade ...

SanofiSNY said Friday its anti-inflammation blockbuster, Dupixent, neared $5 billion in third-quarter sales, easily beating expectations and driving Sanofi stock closer to a breakout. This was the ...

Please provide your email address to receive an email when new articles are posted on . Dupixent previously received priority review and orphan drug designation from the FDA for bullous pemphigoid.

The company will prioritise investment for in-house innovation over large M&A deals, bucking the trend across pharma.